Welcome

Please select one of the links below to access information relevant to you.

Healthcare Professionals*

CONTINUE CONTINUE

Patients on apixaban

CONTINUE CONTINUE

Members of the public

CONTINUE CONTINUE

*This promotional site is only intended for healthcare professionals seeking information on ELIQUIS (apixaban) in Ireland.

Report adverse events (Healthcare Professionals in the Republic of Ireland)

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

Healthcare professionals are asked to report any suspected adverse reactions via Freepost, HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517; Website: www.hpra.ie; E-mail: medsafety@hpra.ie.

Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com.

Report side effects (Patients and Public in the Republic of Ireland)

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

You can also report side effects directly via Freepost, HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517; Website: www.hpra.ie; E-mail: medsafety@hpra.ie.

By reporting side effects you can help provide more information on the safety of this medicine.

Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com.

  • Privacy Policy
  • Legal Notice
  • Pharmacovigilance Notice
  • Contact Us
  • Privacy Policy
  • Legal Notice
  • Pharmacovigilance Notice
  • Contact Us

© 2015 Bristol-Myers Squibb Pharmaceuticals Limited

All corporate names and logos of BMS and/or of its products are trademarks of Bristol-Myers Squibb Company and are protected by national and international intellectual and industrial property laws. All rights reserved over the content of this website.

Pharmacovigilance Notice: This website has not been designed and must not be used to collect or provide safety information related to Bristol-Myers Squibb products. If your query relates to an adverse event experienced by a patient, please contact the Pharmacovigilance Department on 1 800 749 749 (Ireland only freephone number) or +44 1895 523740 (international number) which is available 24 hours a day, 365 days a year, or contact us by email at medical.information@bms.com.

Your use of this website is subject to the Legal Notice, the Privacy and Cookie Policy, the Pharmacovigilance Notice and the applicable laws and regulations.

432IE1600023-01 / ELI/2015/010/1
Date of approval: February 2016

You are about to leave this website

This link takes you to a website of Bristol-Myers Squibb Group or Pfizer Group that may have a different purpose, contents which might not be appropriate for all kinds of public as per the applicable laws, or may have different terms and conditions. The Alliance recommends that you check whether it is suitable for you as per its intended audience and the applicable laws and regulations before accessing it.

If you wish to continue click ‘Continue’, otherwise click ‘Stay on this site’.

Continue Stay on this site

You are about to leave this Website.

This link takes you to a third party website (outside of the Bristol-Myers Squibb Group and Pfizer Group). Bristol-Myers Squibb and Pfizer has no control over the content or management of third party websites nor can it be held responsible or liable for such content or management. Please make sure the contents therein are suitable for you as per its intended audience and the applicable laws and regulations. It is recommended that you carefully read the legal notice and cookies and privacy policy of third party websites before accessing these sites.

If you wish to continue, click ‘Continue’, otherwise click ‘Stay on this site’.

Continue Stay on this site